Similarly, HER2-overexpressing breast cancer patients with PIK3CA mutation or low PTEN expression, both of which result in PI3K pathway activation, are resistant to Herceptin, a HER2 inhibitor [50]. This evidence concerns the gene PTEN and breast carcinoma.